Author:
Kalra Sanjay,Shetty Kimi K.,Nagarajan Vertivel B.,Ved Jignesh K.
Publisher
Springer Science and Business Media LLC
Subject
Endocrinology, Diabetes and Metabolism,Internal Medicine
Reference82 articles.
1. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28.
2. USFDA. Drug Safety Communications. FDA warns that SGLT2 inhibitors for diabetes may result in a serious condition of too much acid in the blood. 2015. https://www.fda.gov/media/92185/download. Accessed 29 Nov 2019.
3. USFDA. Drug Safety Communications. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR). 2017. https://www.fda.gov/media/104870/download. Accessed 29 Nov 2019.
4. Ved J, Paul K, Kalra S. Vasculo-metabolic axis in type 2 diabetes mellitus—abductive reasoning from sodium glucose cotransporter-2 inhibitor evidence. US Endocrinol. 2019;15(1):27–31.
5. Perkovic V, Jardine MJ, Neal B, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. N Engl J Med. 2019;380(24):2295–306.
Cited by
15 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献